ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global
device, cell, and gene therapy-enabling company offering precise
navigation to the brain and spine, today announced that preclinical
results of an in vivo validation study have been published in the
Journal of Neurosurgery.1 These data demonstrate that the
ClearPoint Prism Neuro Laser Therapy System provides accurate, near
real-time temperature of the brain tissue with a mean absolute
error of <1°C. Additionally, the morphology of the lesion, as
visualized by Thermoguide™ MR-thermometry software, correlated well
with histopathology.
The research was conducted by the Company and its Swedish
partner, Clinical Laserthermia Systems AB (CLS), with Dr. John
Rolston leading the study as Principal Investigator. The aim of the
study was to evaluate the safety, accuracy, and efficacy of the
Prism System. This was achieved by 1) demonstrating a predicted
safety margin via survival histology; 2) determining the Thermal
Damage Thresholds (TDTs) that best predict irreversible tissue
damage based on said histology; and 3) evaluating the accuracy of
temperature prediction compared to actual temperature changes in
vivo.
“Our research presents a comprehensive and meticulously
conducted open analysis of the ClearPoint Prism laser system. Prism
offers a seamlessly integrated solution for precise and more
efficient laser interstitial thermal therapy, advancing new
treatment options for patients with intractable epilepsy, movement
disorders, and brain tumors,” said John D. Rolston, MD, PhD,
Associate Professor of Neurosurgery, Harvard Medical School.
“This robust, peer-reviewed validation clearly demonstrates that
the advantages of Prism result in excellent predictability of
targeted cell death. Our comparison of histopathology to damage
estimation is arguably the most definitive test we could have
performed and was part of the dataset that led to FDA clearance,”
commented Chris Osswald, PhD, Director, Global Segment Leader for
Laser Therapy at ClearPoint Neuro.
Additionally, the Prism System has been used together with the
Company’s recently FDA cleared Array software version 1.2 to
improve the practicality of neuro laser therapy. The SmartFrame
Array Neuro Navigation System combines hardware and software
designed to streamline neurosurgical procedures2 and enable more
workflow options for both laser ablation and drug delivery
procedures. Array’s new “Parallel Trajectory” feature allows for
combination biopsy and laser therapy procedures, for example, to be
performed in a single setting, through a single frame alignment,
without the biopsy void interfering with the accuracy of
thermometry.
The Prism System features the only non-cooled neurosurgical
laser applicators on the market. ClearPoint’s next-generation laser
applicator technology eliminates the need for external cooling,
simplifying setup, reducing power and ablation time, lessening
imaging artifact, and enabling more efficient workflows. Currently,
Prism is in limited market release at select academic medical
centers across the United States.
About ClearPoint Neuro
ClearPoint Neuro is a device, cell, and gene therapy-enabling
company offering precise navigation to the brain and spine. The
Company uniquely provides both established clinical products as
well as preclinical development services for controlled drug and
device delivery. The Company’s flagship product, the ClearPoint
Neuro Navigation System, has FDA clearance and is CE-marked.
ClearPoint Neuro is engaged with healthcare and research centers in
North America, Europe, Asia, and South America. The Company is also
partnered with the most innovative pharmaceutical/biotech
companies, academic centers, and contract research organizations,
providing solutions for direct CNS delivery of therapeutics in
pre-clinical studies and clinical trials worldwide. To date,
thousands of procedures have been performed and supported by the
Company’s field-based clinical specialist team, which offers
support and services to our customers and partners worldwide. For
more information, please visit www.clearpointneuro.com
Forward-Looking Statements
This press release contains forward-looking statements within
the context of the federal securities laws, which may include the
Company’s expectation for the future market of its products and
services, and other performance and results. These forward-looking
statements are based on management’s current expectations and are
subject to the risks inherent in the business, which may cause the
Company's actual results to differ materially from those expressed
in or implied by forward-looking statements. Particular
uncertainties and risks include those relating to: global and
political instability, supply chain disruptions, labor shortages,
and macroeconomic and inflationary conditions; future revenue from
sales of the Company’s products and services; the Company’s ability
to market, commercialize and achieve broader market acceptance for
new products and services offered by the Company; the ability of
our biologics and drug delivery partners to achieve commercial
success, including their use of the Company’s products and services
in their delivery of therapies; the Company’s expectations,
projections and estimates regarding expenses, future revenue,
capital requirements, and the availability of and the need for
additional financing; the Company’s ability to obtain additional
funding to support its research and development programs; the
ability of the Company to manage the growth of its business; the
Company’s ability to attract and retain its key employees; and
risks inherent in the research, development, and regulatory
approval of new products. More detailed information on these and
additional factors that could affect the Company’s actual results
are described in the “Risk Factors” section of the Company’s Annual
Report on Form 10-K for the year ended December 31, 2022, and the
Company’s Quarterly Report on Form 10-Q for the three months ended
September 30, 2023, both of which have been filed with the
Securities and Exchange Commission, and the Company’s Annual Report
on Form 10-K for the year ended December 31, 2023, which the
Company intends to file with the Securities and Exchange Commission
on or before March 31, 2024. The Company does not assume any
obligation to update these forward-looking statements.
1 Singh H, Osswald CR, Rossman A, et al. Preclinical assessment
of a noncooled MR thermometry–based neurosurgical laser therapy
system. Journal of Neurosurgery. Published online March 08, 2024.
doi:10.3171/2023.12.JNS2321542 Sterk B, Taha B, Osswald C, Bell R,
Chen L, Chen CC. Initial Clinical Experience With ClearPoint
SmartFrame Array-Aided Stereotactic Procedures. World Neurosurg.
2022;162:e120-e130. doi:10.1016/j.wneu.2022.02.095
Photos accompanying this announcement are available
at:https://www.globenewswire.com/NewsRoom/AttachmentNg/5b6c1042-46f3-43c2-8dc5-7adb98300d25
https://www.globenewswire.com/NewsRoom/AttachmentNg/0118a9fa-7c2e-4aef-8e24-898dbe0f9a63
https://www.globenewswire.com/NewsRoom/AttachmentNg/a6686b2e-206d-4a18-aafe-5d90ec662726
Contact:
Media Contact:
Jacqueline Keller, Vice President of Marketing
(888) 287-9109 ext. 4
info@clearpointneuro.com
Investor Relations:
Danilo D’Alessandro, Chief Financial Officer
(888) 287-9109 ext. 3
ir@clearpointneuro.com
ClearPoint Neuro (NASDAQ:CLPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
ClearPoint Neuro (NASDAQ:CLPT)
Historical Stock Chart
From Apr 2023 to Apr 2024